Efficacy of Subcutaneous Immunoglobulin Replacement Therapy in Treating Secondary Immunodeficiency Disorders

Pranav Vadlamudi, P. Gordon
{"title":"Efficacy of Subcutaneous Immunoglobulin Replacement Therapy in Treating Secondary Immunodeficiency Disorders","authors":"Pranav Vadlamudi, P. Gordon","doi":"10.35248/1745-7580.20.16.6074","DOIUrl":null,"url":null,"abstract":"In 1952, the first immunoglobulin products, made from human plasma, were used to combat infectious diseases such as primary immunodeficiencies during World War II. In addition, during the last 50 years, further research has been conducted to prove whether or not immunoglobulin therapy can truly be effective against primary immunodeficiencies such as X-linked agammaglobulinemia or Common Variable Immunodeficiency Disorder through both intravenous and subcutaneous administration. Intravenous administration has been effective in increasing overall Ig serum concentration in the blood for patients with primary or secondary disorders. However, as more research was conducted, scientists had concluded that the overall cost, maintenance, and at times, lack of efficiency, makes intravenous administration a burden. Thus, scientists have looked for an alternative through subcutaneous administration. For patients with primary immunodeficiencies, subcutaneous has been proven effective in increasing immunoglobulin concentration, even more than intravenous has. The benefit of subcutaneous administration at-home, the low cost, and the heightened efficacy make subcutaneous administration far better than intravenous for primary immunodeficiency patients. However for secondary immunodeficiency patients, the efficacy of subcutaneous administration has not been fully proven and the research is scarce and unreliable. Our literary review explores the advent of immunoglobulin therapy and its past research on both intravenous and subcutaneous administration for primary and secondary immunodeficiency disorders. We sought out to find potential experimental values researchers can conduct experiments to enhance the research on subcutaneous administration for secondary immunodeficiency patients","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"16 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunome research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/1745-7580.20.16.6074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In 1952, the first immunoglobulin products, made from human plasma, were used to combat infectious diseases such as primary immunodeficiencies during World War II. In addition, during the last 50 years, further research has been conducted to prove whether or not immunoglobulin therapy can truly be effective against primary immunodeficiencies such as X-linked agammaglobulinemia or Common Variable Immunodeficiency Disorder through both intravenous and subcutaneous administration. Intravenous administration has been effective in increasing overall Ig serum concentration in the blood for patients with primary or secondary disorders. However, as more research was conducted, scientists had concluded that the overall cost, maintenance, and at times, lack of efficiency, makes intravenous administration a burden. Thus, scientists have looked for an alternative through subcutaneous administration. For patients with primary immunodeficiencies, subcutaneous has been proven effective in increasing immunoglobulin concentration, even more than intravenous has. The benefit of subcutaneous administration at-home, the low cost, and the heightened efficacy make subcutaneous administration far better than intravenous for primary immunodeficiency patients. However for secondary immunodeficiency patients, the efficacy of subcutaneous administration has not been fully proven and the research is scarce and unreliable. Our literary review explores the advent of immunoglobulin therapy and its past research on both intravenous and subcutaneous administration for primary and secondary immunodeficiency disorders. We sought out to find potential experimental values researchers can conduct experiments to enhance the research on subcutaneous administration for secondary immunodeficiency patients
皮下免疫球蛋白替代疗法治疗继发性免疫缺陷疾病的疗效观察
1952年,第一批由人类血浆制成的免疫球蛋白产品在第二次世界大战期间被用于对抗传染病,如原发性免疫缺陷。此外,在过去的50年里,已经进行了进一步的研究,以证明免疫球蛋白治疗是否能够真正有效地通过静脉和皮下给药治疗原发性免疫缺陷,如x连锁无球蛋白血症或常见变异性免疫缺陷疾病。对于原发性或继发性疾病的患者,静脉给药可有效地增加血液中总血清Ig浓度。然而,随着更多的研究进行,科学家们得出结论,总体成本,维护,有时缺乏效率,使静脉注射给药成为一种负担。因此,科学家们一直在寻找通过皮下给药的替代方法。对于原发性免疫缺陷患者,皮下注射已被证明在增加免疫球蛋白浓度方面有效,甚至比静脉注射更有效。对于原发性免疫缺陷患者,家庭皮下给药的好处、低成本和更高的疗效使得皮下给药远远优于静脉注射。然而,对于继发性免疫缺陷患者,皮下给药的疗效尚未得到充分证实,研究较少且不可靠。我们的文献综述探讨了免疫球蛋白疗法的出现及其在原发性和继发性免疫缺陷疾病的静脉注射和皮下注射方面的过去研究。我们寻求潜在的实验价值,研究人员可以进行实验,以加强对继发性免疫缺陷患者皮下给药的研究
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信